Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis

Recruiting

Phase 2

Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis

Sponsor:

Transparency Life Sciences

Code:

NCT02369926

Conditions

Multiple Sclerosis, Relapsing-Remitting

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Not accepted

Interventions

Multiple Sclerosis Functional Composite

Mobile Multiple Sclerosis Functional Composite

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-05. This information was provided to ClinicalTrials.gov by Transparency Life Sciences on 2017-10-12.